NCT06939803 AI-driven Clinical Decision Support to Reduce Hospital-Acquired Venous Thromboembolism: Study Protocol for the VTE-AI Randomized Trial.
| NCT ID | NCT06939803 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Vanderbilt University Medical Center |
| Condition | Venothromboembolism |
| Study Type | INTERVENTIONAL |
| Enrollment | 2,236 participants |
| Start Date | 2025-12-17 |
| Primary Completion | 2026-12-16 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 2,236 participants in total. It began in 2025-12-17 with a primary completion date of 2026-12-16.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Hospital-acquired blood clots (HA-VTE) are the leading cause of death in hospitalized patients in the US. Each year, about 900,000 people get blood clots, costing between $7 and $10 billion in medical expenses. HA-VTE is the second leading cause of long-term disability and causes significant health issues and deaths in both adults and children. About 1 in 3 people who get blood clots experience long-term complications. Reducing HA-VTE is a major challenge. This study will test a new AI method to predict and prevent HA-VTE. The goal is to see if this AI tool can reduce the number of HA-VTE cases in the Vanderbilt Health System, which includes both urban and rural hospitals. The AI tool, called VTE-AI, calculates a risk score without needing input from doctors. It will suggest reconsidering blood clot prevention measures for patients who don't have them ordered and have no reasons to avoid them. This suggestion will be made after admission and daily during the hospital stay. Currently, doctors manually calculate a risk score and choose a prevention option. This study will compare the effectiveness of the AI tool against the current manual method in reducing HA-VTE cases. The study will randomly assign half of the patients to use the AI tool and the other half to the standard manual method.
Eligibility Criteria
Inclusion Criteria: * Inpatient admission to Vanderbilt Adult Hospital, Vanderbilt Tullahoma Harton Hospital, Vanderbilt Bedford County Hospital, or Vanderbilt Wilson County Hospital Exclusion Criteria: * None
Frequently Asked Questions
Who can join the NCT06939803 clinical trial?
This trial is open to participants of all sexes, studying Venothromboembolism. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06939803 currently recruiting?
Yes, NCT06939803 is actively recruiting participants. Visit ClinicalTrials.gov or contact Vanderbilt University Medical Center to inquire about joining.
Where is the NCT06939803 trial being conducted?
This trial is being conducted at Nashville, United States.
Who is sponsoring the NCT06939803 clinical trial?
NCT06939803 is sponsored by Vanderbilt University Medical Center. The trial plans to enroll 2,236 participants.